Response to Omalizumab in Black and White Patients with Allergic Asthma

Stanley J. Szefler, Elina Jerschow, Bongin Yoo, Pranathi Janampally, Hooman Pazwash, Cecile T.J. Holweg, Golda Hudes

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Higher asthma burden is more likely to be experienced by Black than White patients. In clinical research, underrepresentation of minority populations is observed. Objective: To estimate response to omalizumab in Black and White patients in North America with moderate to severe asthma. Methods: Data from placebo-controlled (EXTRA) and single-armed (PROSPERO) omalizumab studies were used for this post hoc analysis. We used a Poisson regression model to examine exacerbation rates. An analysis of covariance model was used to estimate placebo-corrected change in FEV1 and Asthma Quality of Life Questionnaire (AQLQ) by racial group. Results: This analysis included 631 White and 176 Black patients from EXTRA and 567 White and 130 Black patients from PROSPERO. In EXTRA, placebo-corrected exacerbation rate reductions (relative rate change [95% confidence interval], 22.6% [2.0-38.9%] vs 22.0% [−18.0% to 48.4%]) and FEV1 improvements were similar for White and Black patients. There was a trend toward greater AQLQ improvements for Black versus White patients (least squares mean treatment differences: 0.0 vs 0.3, 0.6 vs 0.4, and 0.6 vs 0.2 at weeks 16, 32, and 48, respectively) throughout the study. In PROSPERO, on-study exacerbation rates (0.76 [0.65-0.88] vs 0.77 [0.56-1.10]) and AQLQ improvements (least squares mean change from baseline: 1.2 vs 1.2 and 1.3 vs 1.2 at month 6 and end of study, respectively) were similar for White versus Black patients. A trend toward greater FEV1 improvement was observed in White versus Black patients throughout the study. Conclusions: This analysis of EXTRA and PROSPERO suggests that Black and White patients with moderate to severe asthma experience similar improvements in exacerbations, FEV1, and AQLQ with omalizumab.

Original languageEnglish (US)
Pages (from-to)4021-4028
Number of pages8
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume9
Issue number11
DOIs
StatePublished - Nov 2021

Keywords

  • Asthma
  • Omalizumab
  • Race

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Response to Omalizumab in Black and White Patients with Allergic Asthma'. Together they form a unique fingerprint.

Cite this